Interestingly, the combination of cis-platinum and Olaparib (at ratio of 1:2) was able to overcome the cis-platinum resistance in the NCI-H1975 lung cancer cells transfected with the mutated and truncated CCDC6 isoforms, leading to a synergistic effect of the two drugs (CI < 1), as previously reported in the same cells upon the CCDC6 silencing (Figure 5D) [16]. Here, CCDC6 is linked to lung cancer.